Cargando…

Associations between socioeconomic status and bispecific LV20.19 CAR T-cell therapy outcomes

Detalles Bibliográficos
Autores principales:	Knight, Jennifer M., Hackett, Edward, Szabo, Aniko, Wu, Ruizhe, Sauber, Garrett, Johnson, Bryon, Cusatis, Rachel N., Aughey, Elizabeth, Cole, Steve W., Hillard, Cecilia J., Shah, Nirav N.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2022
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890001/ https://www.ncbi.nlm.nih.gov/pubmed/36200427 http://dx.doi.org/10.3324/haematol.2022.281957

Ejemplares similares

Patient-reported outcomes and neurotoxicity markers in patients treated with bispecific LV20.19 CAR T cell therapy
por: Knight, Jennifer M., et al.
Publicado: (2022)

PD-1 blockade after bispecific LV20.19 CAR T modulates CAR T-cell immunophenotype without meaningful clinical response
por: Zurko, Joanna, et al.
Publicado: (2021)

P1082: RESULTS FROM A PHASE 1/2 STUDY OF TANDEM, BISPECIFIC ANTI-CD20/ANTI-CD19 (LV20.19) CAR T-CELLS FOR MANTLE CELL LYMPHOMA
por: Shah, Nirav N, et al.
Publicado: (2023)

Multi Targeted CAR-T Cell Therapies for B-Cell Malignancies
por: Shah, Nirav N., et al.
Publicado: (2019)

The effect of tocilizumab on patient reported outcomes and inflammatory biomarkers in hematopoietic cell transplantation
por: Taylor, Mallory R., et al.
Publicado: (2022)

Salvage polatuzumab and allogeneic transplant rescue patients with B-cell lymphoma failing CAR T-cell therapy
por: Furqan, Fateeha, et al.
Publicado: (2022)

P1134: BISPECIFIC ANTI-CD20/19 CAR-T – ZAMTOCABTAGENE AUTOLEUCEL FOR RELAPSED/REFRACTORY DLBCL – INTERIM ANALYSIS RESULTS OF DALY-II-USA STUDY
por: Shah, Nirav, et al.
Publicado: (2023)

Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells
por: Thakur, Archana, et al.
Publicado: (2021)

The race is on: bispecifics vs CAR T cells in B-cell lymphoma
por: Gurumurthi, Ashwath, et al.
Publicado: (2023)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in Multiple Myeloma
por: Catamero, Donna, et al.
Publicado: (2022)

Bispecific GPC3/PD-1 CAR-T cells for the treatment of HCC
por: Li, Dezhi, et al.
Publicado: (2023)

Bispecific PSMA antibodies and CAR-T in metastatic castration-resistant prostate cancer
por: Zarrabi, Kevin K., et al.
Publicado: (2023)

Kinetics of Humoral Immunodeficiency With Bispecific Antibody Therapy in Relapsed Refractory Multiple Myeloma
por: Hammons, Lindsay R., et al.
Publicado: (2022)

TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer Immunotherapy
por: Grada, Zakaria, et al.
Publicado: (2013)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

Novel CS1 CAR-T Cells and Bispecific CS1-BCMA CAR-T Cells Effectively Target Multiple Myeloma
por: Golubovskaya, Vita, et al.
Publicado: (2021)

Bispecific Chimeric Antigen Receptor T Cell Therapy for B Cell Malignancies and Multiple Myeloma
por: Cronk, Robert J., et al.
Publicado: (2020)

Different domains of physical activity: The role of leisure, housework/care work, and paid work in socioeconomic differences in reported physical activity
por: Cusatis, Rachel, et al.
Publicado: (2019)

Gut microbiome and CAR-T therapy
por: Abid, Muhammad Bilal, et al.
Publicado: (2019)

Erratum in Volume LV
Publicado: (1841)

Institution Building: LV Prasad Eye Institute
por: Rao, Gullapalli N
Publicado: (2022)

3D Strain helps relating LV function to LV and structure in athletes
por: Stefani, Laura, et al.
Publicado: (2014)

CAR T-cell therapy for secondary CNS DLBCL
por: Ahmed, Gulrayz, et al.
Publicado: (2021)

For LV pacing, four is greater than two
por: Reynolds, Matthew R., et al.
Publicado: (2017)

High efficacy and safety of CD38 and BCMA bispecific CAR-T in relapsed or refractory multiple myeloma
por: Tang, Yuanyan, et al.
Publicado: (2022)

Cryopreserved anti-CD22 and bispecific anti-CD19/22 CAR T cells are as effective as freshly infused cells
por: Dreyzin, Alexandra, et al.
Publicado: (2022)

Embolised ASD device in LV
por: Raut, Monish S., et al.
Publicado: (2016)

Dr. Lothrop.—Volume LV
Publicado: (1899)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

Systematically optimized BCMA/CS1 bispecific CAR-T cells robustly control heterogeneous multiple myeloma
por: Zah, Eugenia, et al.
Publicado: (2020)

Fully human antibody V(H) domains to generate mono and bispecific CAR to target solid tumors
por: Wang, Guanmeng, et al.
Publicado: (2021)

A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
por: Mei, Heng, et al.
Publicado: (2021)

Nanobody-derived bispecific CAR-T cell therapy enhances the anti-tumor efficacy of T cell lymphoma treatment
por: Xia, Baijin, et al.
Publicado: (2023)

Rap1A, Rap1B, and β-Adrenergic Signaling in Autologous HCT: A Randomized Controlled Trial of Propranolol
por: Johnson, Alexander K., et al.
Publicado: (2022)

Circulating endocannabinoid concentrations in grieving adults
por: Harfmann, Elisabeth J., et al.
Publicado: (2020)

LV wall motion assessment during regadenoson vasodilator stress CMR
por: Jesinger, Michael, et al.
Publicado: (2016)

Efficacy of a third SARS-CoV-2 mRNA vaccine dose among hematopoietic cell transplantation, CAR T cell, and BiTE recipients
por: Abid, Muhammad Bilal, et al.
Publicado: (2022)

A sensitivity scale for targeting T cells with chimeric antigen receptors (CARs) and bispecific T-cell Engagers (BiTEs)
por: Stone, Jennifer D., et al.
Publicado: (2012)

Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma
por: Jiang, Wei, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_td1p9mujilhqn1eaoaunup9nun